FLT3 inhibitors such as gilteritinib and midostaurin target acute myeloid leukemia with FLT3 mutations, while FGFR inhibitors such as erdafitinib are used for urothelial carcinoma [93,94]. Here, FLT3 is linked to urothelial carcinoma.